Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN8QAF)

• Drug Name: 8-aminoquinolines Drug Info
• Synonyms: Hexamethonium; hexamethonium; Hexonium; Benzohexamethonium; Hexamethonum; Bistrium; Hexanium; 60-26-4; UNII-3C9PSP36Z2; Esametonio [Italian]; CHEMBL100622; CHEBI:5700; 3C9PSP36Z2; N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium; NCGC00163239-01; Hexane-1,6-bis(trimethylammonium); 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-; DSSTox_RID_80651; DSSTox_CID_25053; DSSTox_GSID_45053; BRN 1760389; Esametonio; CHEMBL332524; CAS-60-26-4; Hexamethonium [INN]; Ammonium, hexamethylenebis(trimethyl-; trimethyl-[6-(trimethylazaniumyl)hexyl]azanium

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3604
  ChEBI ID: CHEBI:5700
  CAS Number: CAS 60-26-4
  TTD Drug ID: DMN8QAF

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[4]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[5]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[6]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[9]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[9]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[10]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[9]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[11]
Cotinine	DMCEZ1B	Insecticide	N.A.	Approved	[12]
Pancuronium	DMB0VY8	Anaesthesia	9A78.6	Approved	[13]
Atracurium	DM42HXN	Anaesthesia	9A78.6	Approved	[13]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[14]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[15]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[16]
BMS-954561	DM7XV4R	Diabetic neuropathy	8C0Z	Phase 2	[17]
ASM-024	DM35S2I	Asthma	CA23	Phase 2	[18]
NIC-002	DMKLJMI	Nicotine dependence	6C4A.2	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Antagonist	[2]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3963).
• [2] Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994 Oct;5(10):1033-40.
• [3] The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp Parasitol. 1994 Aug;79(1):50-6.
• [4] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [5] Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
• [6] Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
• [7] Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
• [8] Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
• [11] Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
• [12] Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
• [13] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
• [14] Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [17] EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
• [18] Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
• [19] Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.